Trial reportPloS one2025
The effect of Nigella Sativa emulgel on episiotomy wound healing and pain intensity in primiparous women: A triple-blind randomized controlled trial.
Trial report in PloS one, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundEpisiotomy, a common surgical procedure during childbirth, often leads to complications such as pain, infection, and delayed healing. Nigella sativa has demonstrated anti-inflammatory and wound-healing properties in prior studies and have received United States Food and Drug Administration (FDA) approval for food use, indicating their safety. This study aimed to evaluate the efficacy of Nigella sativa emulgel on episiotomy wound healing and pain intensity in primiparous women.
methodsA triple-blind, randomized controlled trial was conducted at Taleghani Hospital, Tabriz, Iran (May 2023-April 2024). Seventy-four primiparous women with mediolateral episiotomy were randomized to receive either Nigella sativa emulgel or placebo, applied topically three times daily for 7 days post-discharge. Wound healing was assessed using the REEDA scale (Redness, Edema, Ecchymosis, Discharge, Approximation; primary outcome), and pain intensity was measured via visual analog scale (VAS; secondary outcome). Outcomes were evaluated at discharge (baseline) and 10 ± 1 days postpartum. Data were analyzed using independent t-tests, ANCOVA (adjusted for baseline scores), and Mann-Whitney U tests for non-normal distributions (SPSS v26).
resultsAt 10 ± 1 days postpartum, the Nigella sativa group showed significantly better wound healing (REEDA score: MD -0.79, 95% CI -1.20 to -0.39; p = 0.001) and lower pain scores (VAS: MD -0.74, 95% CI -1.3 to -0.11; p = 0.021) compared to placebo. Subscale analysis revealed improvements in redness (p = 0.037), edema (p = 0.041), and ecchymosis (p = 0.043). No adverse effects were reported, and satisfaction was higher in the Nigella sativa group (86.5% vs. 56.7%; p = 0.046).
conclusionsTopical Nigella sativa emulgel significantly improved episiotomy wound healing and reduced pain intensity, with high patient satisfaction. These findings support its potential as a natural therapeutic option, though larger multi-center trials are needed for broader validation.
trial registrationIranian Registry of Clinical Trials IRCT20120718010324N68.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.